Abstract
Abbott Laboratories will report its second-quarter 2026 results on July 16, 2026 Pre-Market; this preview summarizes consensus expectations for revenue, margin and EPS, recaps last quarter’s performance, outlines the quarter’s key operating drivers by business, and distills how institutional opinion is skewed ahead of the print.
Market Forecast
Consensus points to solid top-line expansion for the current quarter: revenue is estimated at 12.50 billion US dollars, up 12.92% year over year; adjusted EPS is projected at 1.28, up 1.96% year over year; and EBIT is projected at 2.77 billion US dollars, up 10.81% year over year.
Within the business mix, last quarter’s revenue drivers were Medical Devices at 5.54 billion US dollars, Diagnostics at 2.18 billion US dollars, Nutrition at 2.02 billion US dollars, and Established Pharmaceuticals at 1.43 billion US dollars, with the product and geographic balance supporting resilient profitability.
The most promising near-term growth contributor remains Diabetes Care within Medical Devices (including the FreeStyle Libre franchise), supported by ongoing product upgrades and regulatory catalysts; this franchise is captured within the 5.54 billion US dollars medical devices line, and consensus commentary implies continued unit expansion through 2026.
Last Quarter Review
In the first quarter of 2026, Abbott Laboratories generated 11.16 billion US dollars of revenue (+7.78% year over year), delivered a gross profit margin of 56.20%, posted GAAP net profit attributable to shareholders of 1.08 billion US dollars with a net profit margin of 9.65%, and reported adjusted EPS of 1.15 (+5.51% year over year).
A notable financial highlight was a modest beat versus consensus on both the top and bottom lines, with revenue surpassing expectations by 0.17 billion US dollars and EPS landing slightly above the street’s modeled figure.
In terms of business composition, Medical Devices contributed 5.54 billion US dollars, Diagnostics 2.18 billion US dollars, Nutrition 2.02 billion US dollars, and Established Pharmaceuticals 1.43 billion US dollars; at the consolidated level, the 7.78% year-over-year revenue growth reflected balanced demand across the portfolio with a favorable margin mix.
Current Quarter Outlook
Medical Devices
Medical Devices remains the primary earnings engine this quarter given its scale and leverage to procedure volumes and ongoing innovation cycles. The 5.54 billion US dollars delivered last quarter set a constructive base, and incoming product clearances reinforce the cadence of upgrades that can lift utilization in cardiology and structural heart categories. Regulatory clearance of the Ultreon 3.0 coronary imaging software underscores the continued refresh of the coronary toolkit, which can support pull-through of associated hardware and consumables. Procedural activity trends into the mid-year period typically stabilize seasonally, and a steady hospital purchasing environment should help volumes hold up. Mix shifts within devices tend to be margin-accretive relative to the corporate average, which is relevant for this quarter given consensus is looking for revenue growth to convert to EBIT expansion. Currency effects and regional purchasing timelines can introduce noise, but the setup is for mid-teens consolidated revenue growth with devices acting as a steady contributor.
Diabetes Care and the FreeStyle Libre Franchise
The Diabetes Care franchise, anchored by FreeStyle Libre, stands out as the most promising growth platform in 2026, with analysts highlighting expanding adoption curves and the roadmap toward integrated offerings such as Libre Duo. While the tool-reported revenue is embedded within the 5.54 billion US dollars devices line, commentary across the street points to continued unit growth, new-to-system users, and upgrades that collectively support durable midterm expansion. The case for this quarter centers on three elements: steady new patient starts, higher sensor utilization per user as engagement deepens, and the ongoing extension of indications and connectivity that broaden addressable use. The forward path for next-generation systems is a focus for investors because feature upgrades tend to improve retention while nudging average revenue per patient. Any color on reimbursement updates, geographic rollouts, or progress toward more advanced integrated systems could influence the second-half trajectory and frame expectations for 2027 earnings acceleration referenced by multiple analysts.
Key Stock-Price Swing Factors This Quarter
Investors will parse the revenue print and commentary on margins in the context of the prior quarter’s 56.20% gross margin and 9.65% net margin; the degree to which this quarter’s mix skews toward higher-margin devices versus lower-margin diagnostics will inform EBIT flow-through. Regulatory momentum has continued into mid-2026, including clearance for Ultreon 3.0 coronary imaging software and approval of the HIV Combo Next test, both of which speak to innovation breadth and can support medium-term diagnostics and cardiovascular revenue streams. The announced global licensing arrangement to incorporate phosphorylated Tau 217 antibodies into Alzheimer’s-related diagnostic development further illustrates pipeline optionality, and any updated timelines or early adoption perspectives could affect sentiment. On capital allocation, the quarterly dividend of 0.63 per share reinforces balance-sheet confidence; any commentary about repurchases or ongoing investment priorities will be read alongside the CFO’s recent insider purchase that caught investor attention earlier in the quarter. Finally, the full-year guide and second-half visibility will be pivotal; bridging the implied step-up from the 11.16 billion US dollars last quarter to the 12.50 billion US dollars consensus in the current quarter will require clarity on utilization, pricing, and the cadence of new product ramp.
Analyst Opinions
The ratio of bullish to bearish/neutral published views over the past six months is decisively tilted positive, with roughly nine bullish notes versus one downgrade to neutral, implying about 90% bullish and 10% neutral/bearish. The prevailing view emphasizes confidence in the devices-and-diabetes growth drivers, continued regulatory wins in diagnostics and cardiovascular imaging, and the potential for multi-year earnings compounding as product cycles unfold.
Citi reaffirmed a Buy on July 6, 2026 with a 108.00 US dollars target, pointing to durable execution and visibility across core product lines. Wells Fargo maintained a Buy and a 109.00 US dollars target in recent updates, highlighting steady device momentum and incremental contributions from new approvals. Bank of America reiterated a Buy with a 120.00 US dollars target, explicitly calling out the Libre Duo opportunity and projecting accelerating earnings into 2027 as the diabetes franchise scales. UBS kept a Buy with a 135.00 US dollars target, citing the platform’s breadth and the durability of cash flows that can support both reinvestment and shareholder returns. RBC Capital also maintained a Buy with a 135.00 US dollars target, underscoring the same portfolio themes and focusing investors on the path to multi-year product cycle benefits.
Several institutions adjusted targets to reflect market conditions while retaining constructive stances: Evercore ISI updated its price target to 112.00 US dollars and Goldman Sachs trimmed its target to 113.00 US dollars while maintaining Buy ratings, both signaling confidence in fundamental drivers despite a more measured valuation framework. Baird initiated at Outperform with a 121.00 US dollars target, adding another positive voice to the consensus. Against this backdrop, a single downgrade to Neutral from Daiwa in late April with a 92.00 US dollars target stands out as the minority view; it did not shift the broader balance of opinion, which remains supportive.
Synthesizing these perspectives, the majority case anticipates that second-quarter revenue growth of 12.92% year over year will be supported by continued adoption in Diabetes Care, contributions from new cardiovascular software approvals, and steady diagnostics activity. The bullish camp expects adjusted EPS growth to resume its trajectory as mix and operating discipline allow a portion of the top-line outperformance to fall through to EBIT, consistent with the 10.81% year-over-year increase implied by the EBIT estimate of 2.77 billion US dollars. As a group, these institutions see near-term execution and the maturing innovation pipeline as sufficient to carry the company through the second half, even as they watch for updates on reimbursement dynamics, launch pacing, and any incremental guide changes on July 16, 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments